Theratechnologies (TSE:TH) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Theratechnologies has filed a Prior Approval Supplement with the FDA for changes in the manufacturing environment of EGRIFTA SV®, with existing inventory expected to meet demand until mid-January 2025. The company is in discussions with the FDA to expedite the release and prevent a potential product shortage. Theratechnologies will keep the market informed of any significant developments.
For further insights into TSE:TH stock, check out TipRanks’ Stock Analysis page.
